Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 8Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Radiation Injuries 1Prostatic Neoplasms 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Frailty 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Androgen Antagonists 9darolutamide 6Magnetic Resonance Spectroscopy 6enzalutamide 5apalutamide 5Docetaxel 5Specimen Handling 4Radiotherapy 4Abiraterone Acetate 4Prednisone 3Electroacupuncture 3Brachytherapy 3pembrolizumab 2Standard of Care 2Resistance Training 2Radiosurgery 2Radiation 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1fezolinetant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × Photons × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡